India, April 7 -- US based Luminex Corporation hasannounced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its ARIES(R)SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19.

The assay runs on the ARIES(R)System, an FDA-cleared, sample-to-answer, automated, on-demand molecular diagnostic platform. The system is capable of running up to 144 tests per day, requiring no specialty training and minimal human interaction.

"The ARIES(R)SARS-CoV-2 Assay will allow hospital professionals to determine the appropriate course of treatment for patients suspected of having COVID-19 within approximately two hours," saidNachum "Homi" Shamir, President and CEO of Luminex. "We are grateful ...